增殖性狼疮性肾炎的免疫抑制治疗：Cochrane系统评价总结 - Suppr

Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.

作者信息

Tunnicliffe David J, Palmer Suetonia C

机构信息

Sydney School of Public Health, University of Sydney, NSW, Australia; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia.

Department of Medicine, University of Otago, Christchurch, New Zealand.

出版信息

Am J Kidney Dis. 2018 Nov;72(5):756-757. doi: 10.1053/j.ajkd.2018.07.008.

DOI:10.1053/j.ajkd.2018.07.008

PMID:30343732

Abstract

摘要

相似文献

Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.

Am J Kidney Dis. 2018 Nov;72(5):756-757. doi: 10.1053/j.ajkd.2018.07.008.

Updates on the treatment of lupus nephritis.

J Am Soc Nephrol. 2010 Dec;21(12):2028-35. doi: 10.1681/ASN.2010050472. Epub 2010 Nov 4.

Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.

Nat Clin Pract Nephrol. 2006 Jun;2(6):314-5. doi: 10.1038/ncpneph0184.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Mar 4;350(10):971-80. doi: 10.1056/NEJMoa031855.

The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide.

Intern Med. 2010;49(9):823-8. doi: 10.2169/internalmedicine.49.2291. Epub 2010 Apr 30.

Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.

J Rheumatol. 2015 Nov;42(11):2082-91. doi: 10.3899/jrheum.150395. Epub 2015 Sep 15.

Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil.

J Pediatr Health Care. 2008 Sep-Oct;22(5):282-8. doi: 10.1016/j.pedhc.2007.07.006. Epub 2008 Mar 4.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Jun 10;350(24):2518-20; author reply 2518-20.

Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide.

Nat Clin Pract Rheumatol. 2006 Jul;2(7):354-5. doi: 10.1038/ncprheum0217.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Jun 10;350(24):2518-20; author reply 2518-20. doi: 10.1056/NEJM200406103502416.

引用本文的文献

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.

Effects of alternative remission criteria on outcome of pediatric proliferative lupus nephritis: a multi-center retrospective study of pediatric proliferative lupus nephritis.

Am J Transl Res. 2021 May 15;13(5):4510-4520. eCollection 2021.

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.

Int J Mol Sci. 2021 Jan 27;22(3):1263. doi: 10.3390/ijms22031263.

Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide.

Kidney Dis (Basel). 2020 Sep;6(5):355-363. doi: 10.1159/000509767. Epub 2020 Jul 28.

Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.

Medicine (Baltimore). 2020 Sep 18;99(38):e22328. doi: 10.1097/MD.0000000000022328.

Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up.

J Nephrol. 2021 Apr;34(2):389-398. doi: 10.1007/s40620-020-00753-w. Epub 2020 May 27.

An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?

Am J Kidney Dis. 2018 Nov;72(5):758-760. doi: 10.1053/j.ajkd.2018.07.007.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.

作者信息

Tunnicliffe David J, Palmer Suetonia C

机构信息

Sydney School of Public Health, University of Sydney, NSW, Australia; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia.

Department of Medicine, University of Otago, Christchurch, New Zealand.

出版信息

Am J Kidney Dis. 2018 Nov;72(5):756-757. doi: 10.1053/j.ajkd.2018.07.008.

DOI:10.1053/j.ajkd.2018.07.008

PMID:30343732

Abstract

摘要

相似文献

Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.

Am J Kidney Dis. 2018 Nov;72(5):756-757. doi: 10.1053/j.ajkd.2018.07.008.

Updates on the treatment of lupus nephritis.

J Am Soc Nephrol. 2010 Dec;21(12):2028-35. doi: 10.1681/ASN.2010050472. Epub 2010 Nov 4.

Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.

Nat Clin Pract Nephrol. 2006 Jun;2(6):314-5. doi: 10.1038/ncpneph0184.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Mar 4;350(10):971-80. doi: 10.1056/NEJMoa031855.

The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide.

Intern Med. 2010;49(9):823-8. doi: 10.2169/internalmedicine.49.2291. Epub 2010 Apr 30.

Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.

J Rheumatol. 2015 Nov;42(11):2082-91. doi: 10.3899/jrheum.150395. Epub 2015 Sep 15.

Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil.

J Pediatr Health Care. 2008 Sep-Oct;22(5):282-8. doi: 10.1016/j.pedhc.2007.07.006. Epub 2008 Mar 4.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Jun 10;350(24):2518-20; author reply 2518-20.

Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide.

Nat Clin Pract Rheumatol. 2006 Jul;2(7):354-5. doi: 10.1038/ncprheum0217.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Jun 10;350(24):2518-20; author reply 2518-20. doi: 10.1056/NEJM200406103502416.

引用本文的文献

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.

Effects of alternative remission criteria on outcome of pediatric proliferative lupus nephritis: a multi-center retrospective study of pediatric proliferative lupus nephritis.

Am J Transl Res. 2021 May 15;13(5):4510-4520. eCollection 2021.

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.

Int J Mol Sci. 2021 Jan 27;22(3):1263. doi: 10.3390/ijms22031263.

Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide.

Kidney Dis (Basel). 2020 Sep;6(5):355-363. doi: 10.1159/000509767. Epub 2020 Jul 28.

Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.

Medicine (Baltimore). 2020 Sep 18;99(38):e22328. doi: 10.1097/MD.0000000000022328.

Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up.

J Nephrol. 2021 Apr;34(2):389-398. doi: 10.1007/s40620-020-00753-w. Epub 2020 May 27.

An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?

Am J Kidney Dis. 2018 Nov;72(5):758-760. doi: 10.1053/j.ajkd.2018.07.007.

Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.

作者信息

机构信息

出版信息

相似文献

引用本文的文献